{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:04:02Z","timestamp":1790960642961,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Beijing Major Respiratory Infectious Disease Research Center Project","award":["BJRID225-013"],"award-info":[{"award-number":["BJRID225-013"]}]},{"name":"Excellent Clinical Research Program for Research Wards of Beijing Municipal Health Commission","award":["BRWEP2024W042160109"],"award-info":[{"award-number":["BRWEP2024W042160109"]}]},{"name":"Beijing Medical Management Center Yangfan 3.0 Project","award":["ZLRK202331"],"award-info":[{"award-number":["ZLRK202331"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40121-025-01256-6","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:00:23Z","timestamp":1764669623000},"page":"43-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Tao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-3752","authenticated-orcid":false,"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"1256_CR1","unstructured":"Global tuberculosis report 2024. Geneva: World Health Organization; 2024."},{"issue":"9","key":"1256_CR2","first-page":"859","volume":"43","author":"Beijing Chest Hospital, Capital Medical University\/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis","year":"2021","unstructured":"Beijing Chest Hospital, Capital Medical University\/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 edition). Chin J Antituber. 2021;43(9):859\u201366.","journal-title":"Chin J Antituber"},{"issue":"13","key":"1256_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"1256_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z Lan","year":"2020","unstructured":"Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020;8(4):383\u201394.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1256_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1021\/acsmedchemlett.4c00114","volume":"15","author":"RT Girase","year":"2024","unstructured":"Girase RT, Ahmad I, Oh JM, et al. Design and synthesis of the linezolid bioisosteres to resolve the serotonergic toxicity associated with linezolid. ACS Med Chem Lett. 2024;15(6):924\u201337.","journal-title":"ACS Med Chem Lett"},{"key":"1256_CR6","unstructured":"Barbachyn MR, Harris CR, Josyula VPVN. Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agent. 2005. https:\/\/www.surechembl.org\/document\/WO-2005113520-A1. Accessed 2025 June 17."},{"issue":"11","key":"1256_CR7","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1021\/jm401931e","volume":"57","author":"MF Gordeev","year":"2014","unstructured":"Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014;57(11):4487\u201397.","journal-title":"J Med Chem"},{"issue":"2","key":"1256_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijantimicag.2003.11.003","volume":"23","author":"B Bozdogan","year":"2004","unstructured":"Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23(2):113\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"1256_CR9","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1128\/AAC.01113-06","volume":"51","author":"E Richter","year":"2007","unstructured":"Richter E, R\u00fcsch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51(4):1534\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1256_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.955050","volume":"13","author":"T Azimi","year":"2022","unstructured":"Azimi T, Khoshnood S, Asadi A, et al. Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: a systematic review and meta-analysis. Front Pharmacol. 2022;13:955050.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1256_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5588\/ijtld.22.0632","volume":"27","author":"D Vengurlekar","year":"2023","unstructured":"Vengurlekar D, Walker C, Mahajan R, et al. Linezolid resistance in patients with drug-resistant TB. Int J Tuberc Lung Dis. 2023;27(7):567\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"1256_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00131-9","volume":"5","author":"S Pei","year":"2024","unstructured":"Pei S, Song Z, Yang W, et al. The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis. Lancet Microbe. 2024;5(11):100899.","journal-title":"Lancet Microbe"},{"key":"1256_CR13","unstructured":"WHO. Catalogue of mutations in mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed. https:\/\/www.who.int\/publications\/i\/item\/9789240082410. Accessed 2025 July 17."},{"issue":"6","key":"1256_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/ph16060784","volume":"16","author":"WC Gan","year":"2023","unstructured":"Gan WC, Ng HF, Ngeow YF. Mechanisms of linezolid resistance in mycobacteria. Pharmaceuticals (Basel). 2023;16(6):784.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"1256_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00789-23","volume":"67","author":"D Almeida","year":"2023","unstructured":"Almeida D, Li SY, Lee J, et al. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrob Agents Chemother. 2023;67(12):e0078923.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1256_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01034-22","volume":"66","author":"R Pi","year":"2022","unstructured":"Pi R, Chen X, Meng J, et al. Drug degradation caused by mce3R mutations confers contezolid (MRX-I) resistance in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022;66(10):e0103422.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1256_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/pathogens14030218","volume":"14","author":"J Dong","year":"2025","unstructured":"Dong J, Cheng Q, Tang C, et al. Comparative in vitro drug susceptibility study of five oxazolidinones against Mycobacterium tuberculosis in Hainan, China. Pathogens. 2025;14(3):218.","journal-title":"Pathogens"},{"issue":"5","key":"1256_CR18","doi-asserted-by":"publisher","first-page":"e0462722","DOI":"10.1128\/spectrum.04627-22","volume":"11","author":"H An","year":"2023","unstructured":"An H, Sun W, Liu X, Wang T, Qiao J, Liang J. In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis. Microbiol Spectr. 2023;11(5):e0462722.","journal-title":"Microbiol Spectr"},{"issue":"8","key":"1256_CR19","doi-asserted-by":"publisher","first-page":"e00493","DOI":"10.1128\/AAC.00493-18","volume":"62","author":"C Shoen","year":"2018","unstructured":"Shoen C, DeStefano M, Hafkin B, Cynamon M. In vitro and in vivo activities of contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(8):e00493-e518.","journal-title":"Antimicrob Agents Chemother"},{"key":"1256_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1067516","volume":"9","author":"C Wang","year":"2022","unstructured":"Wang C, Wang G, Huo F, et al. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China. Front Med. 2022;9:1067516.","journal-title":"Front Med"},{"issue":"4","key":"1256_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01655-22","volume":"67","author":"DA Negatu","year":"2023","unstructured":"Negatu DA, Aragaw WW, Cangialosi J, Dartois V, Dick T. Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections. Antimicrob Agents Chemother. 2023;67(4):e01655\u201322.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1256_CR22","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41579-022-00763-4","volume":"20","author":"P Chandra","year":"2022","unstructured":"Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol. 2022;20(12):750\u201366.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"1256_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00035-23","volume":"67","author":"SY Li","year":"2023","unstructured":"Li SY, Converse PJ, Betoudji F, et al. Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model. Antimicrob Agents Chemother. 2023;67(4):e0003523.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1256_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/jac\/45.6.859","volume":"45","author":"FA Sirgel","year":"2000","unstructured":"Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother. 2000;45(6):859\u201370.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1256_CR25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1164\/rccm.2302003","volume":"167","author":"WJ Burman","year":"2003","unstructured":"Burman WJ. The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment. Am J Respir Crit Care Med. 2003;167(10):1299\u2013301.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"1256_CR26","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1128\/AAC.01354-09","volume":"54","author":"AH Diacon","year":"2010","unstructured":"Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54(8):3402\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1256_CR27","first-page":"987","volume":"43","author":"Y Lu","year":"2008","unstructured":"Lu Y, Chu N. Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs. Chin J Antituberc. 2008;43(10):987\u201392.","journal-title":"Chin J Antituberc"},{"issue":"11","key":"1256_CR28","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","volume":"178","author":"R Dietze","year":"2008","unstructured":"Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178(11):1180\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"1256_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/IDR.S499816","volume":"18","author":"G Jiang","year":"2025","unstructured":"Jiang G, Liu R, Xue Y, et al. Contezolid harbored equivalent efficacy to linezolid in tuberculosis treatment in a prospective and randomized early bactericidal activity study. Infect Drug Resist. 2025;18:261\u20138.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"1256_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01684-21","volume":"66","author":"JS Kim","year":"2022","unstructured":"Kim JS, Kim YH, Lee SH, et al. Early bactericidal activity of delpazolid (LCB01-0371) in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2022;66(2):e0168421.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1256_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094462","volume":"9","author":"RS Wallis","year":"2014","unstructured":"Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS ONE. 2014;9(4):e94462.","journal-title":"PLoS ONE"},{"key":"1256_CR32","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.2147\/IDR.S516991","volume":"18","author":"J Wang","year":"2025","unstructured":"Wang J, Xue Y, Nie W, Ma L, Chu N, Du Y. Safety and tolerability of contezolid versus linezolid for short-term treatment of rifampicin-resistant pulmonary tuberculosis: a randomized controlled study. IDR. 2025;18:3307\u201315.","journal-title":"IDR"},{"key":"1256_CR33","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.2147\/IDR.S425743","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, Nie W, Ma L, et al. Clinical utility of contezolid-containing regimens in 25 cases of linezolid-intolerable tuberculosis patients. Infect Drug Resist. 2023;16:6237\u201345.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"1256_CR34","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.21037\/jtd-2025-878","volume":"17","author":"Y Liu","year":"2025","unstructured":"Liu Y, Cui Z, Fu Y, Chan ED, Hu C. Clinical outcomes of contezolid in treating complex tuberculosis: real-world evidence from 11 patients. J Thorac Dis. 2025;17(5):3318\u201325.","journal-title":"J Thorac Dis"},{"issue":"25","key":"1256_CR35","first-page":"00213","volume":"S1473\u20133099","author":"N Heinrich","year":"2025","unstructured":"Heinrich N, Manyama C, Koele SE, et al. Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase\u00a02b dose-finding trial. Lancet Infect Dis. 2025;S1473\u20133099(25):00213.","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"1256_CR36","first-page":"00289","volume":"S1473\u20133099","author":"LT Minja","year":"2025","unstructured":"Minja LT, van der Feltz I, Manyama C, et al. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase\u00a02b, dose-finding trial. Lancet Infect Dis. 2025;S1473\u20133099(25):00289.","journal-title":"Lancet Infect Dis"},{"issue":"02","key":"1256_CR37","first-page":"123","volume":"21","author":"X Li","year":"2024","unstructured":"Li X, Zhang H, Kuang H. Clinical practice analysis of use of contezolid in leukopenic patients with pre-extensively drug-resistant pulmonary tuberculosis. Anti Infect Pharm. 2024;21(02):123\u201330.","journal-title":"Anti Infect Pharm"},{"issue":"04","key":"1256_CR38","first-page":"305","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Sun Y, Chang T, Liu F, Zhao Z, Xiong Y. A case of multi-organ tuberculosis treated with oral chemotherapy regimen containing concomitant zolamide. Chin J Clin Infect Dis. 2024;17(04):305\u20138.","journal-title":"Chin J Clin Infect Dis"},{"issue":"08","key":"1256_CR39","first-page":"529","volume":"41","author":"N Yan","year":"2023","unstructured":"Yan N, Wang Q, Wang J, Chu N, Nie W. Contezolid-based all-oral chemotherapy in pre-XDR tuberculosis: a case study. Chin J Clin Infect Dis. 2023;41(08):529\u201331.","journal-title":"Chin J Clin Infect Dis"},{"issue":"11","key":"1256_CR40","first-page":"1327","volume":"46","author":"X Li","year":"2024","unstructured":"Li X, Xing W, Wang Q, Chu N, Nie W. An all-oral shortened regimen containing new drugs to treat MDR\/rifampicin-resistan ttuberculosis:three case reports and literature review. Chin J Antituberc. 2024;46(11):1327\u201334.","journal-title":"Chin J Antituberc"},{"issue":"04","key":"1256_CR41","first-page":"527","volume":"47","author":"W Huang","year":"2025","unstructured":"Huang W, Yuan C, Chen X, Shang H, Xu Y, Hu M. Successful contezolid replacement therapy for linezolid-intolerant DR-TB: a case study. Chin J Antituberc. 2025;47(04):527\u201330.","journal-title":"Chin J Antituberc"},{"issue":"1","key":"1256_CR42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12879-024-09431-9","volume":"24","author":"W Fu","year":"2024","unstructured":"Fu W, Deng ZW, Wang P, et al. A complex case study: coexistence of multi-drug-resistant pulmonary tuberculosis, HBV-related liver failure, and disseminated cryptococcal infection in an AIDS patient. BMC Infect Dis. 2024;24(1):533.","journal-title":"BMC Infect Dis"},{"key":"1256_CR43","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.2147\/IDR.S469509","volume":"17","author":"YJ Xiong","year":"2024","unstructured":"Xiong YJ, Xiao Y, Xie L, et al. Contezolid for the treatment of drug-resistant tuberculosis in China: a clinical case series. Infect Drug Resist. 2024;17:3491\u20139.","journal-title":"Infect Drug Resist"},{"key":"1256_CR44","doi-asserted-by":"publisher","first-page":"1258561","DOI":"10.3389\/fcimb.2023.1258561","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Yu Z, Jiang Y, Lao S, Li D. Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review. Front Cell Infect Microbiol. 2023;13:1258561.","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"1256_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.70001","volume":"12","author":"L Zhou","year":"2024","unstructured":"Zhou L, Wang Y, Zhou J. Successful treatment of severe tuberculosis with contezolid add-on regimen in a patient complicated with acute thrombocytopenia: a case report. Clin Case Rep. 2024;12(12):e70001.","journal-title":"Clin Case Rep"},{"key":"1256_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1265923","volume":"10","author":"J Wang","year":"2023","unstructured":"Wang J, Ma L. Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review. Front Med. 2023;10:1265923.","journal-title":"Front Med"},{"issue":"2","key":"1256_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5455\/msm.2018.30.153-156","volume":"30","author":"V Cukic","year":"2018","unstructured":"Cukic V, Ustamujic A. Extrapulmonary tuberculosis in Federation of Bosnia and Herzegovina. Mater Sociomed. 2018;30(2):153\u20136.","journal-title":"Mater Sociomed"},{"issue":"8","key":"1256_CR48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S1474-4422(19)30154-1","volume":"18","author":"J Donovan","year":"2019","unstructured":"Donovan J, Figaji A, Imran D, Phu NH, Rohlwink U, Thwaites GE. The neurocritical care of tuberculous meningitis. Lancet Neurol. 2019;18(8):771\u201383.","journal-title":"Lancet Neurol"},{"key":"1256_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2022.12.005","volume":"128","author":"T Li","year":"2023","unstructured":"Li T, Yan X, Du X, et al. Extrapulmonary tuberculosis in China: a national survey. Int J Infect Dis. 2023;128:69\u201377.","journal-title":"Int J Infect Dis"},{"key":"1256_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijid.2021.11.019","volume":"115","author":"W Kang","year":"2022","unstructured":"Kang W, Liu S, Du J, et al. Epidemiology of concurrent extrapulmonary tuberculosis in inpatients with extrapulmonary tuberculosis lesions in China: a large-scale observational multi-centre investigation. Int J Infect Dis. 2022;115:79\u201385.","journal-title":"Int J Infect Dis"},{"key":"1256_CR51","unstructured":"WHO consolidated guidelines on tuberculosis: Module 4: Treatment and care [Internet]. Geneva: World Health Organization; 2025. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240107243. Accessed 2025 July 17."},{"issue":"4","key":"1256_CR52","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/infdis\/jiad413","volume":"229","author":"N Abdelgawad","year":"2024","unstructured":"Abdelgawad N, Wasserman S, Abdelwahab MT, et al. Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis. J Infect Dis. 2024;229(4):1200\u20138.","journal-title":"J Infect Dis"},{"issue":"8","key":"1256_CR53","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/cid\/ciac932","volume":"76","author":"AG Davis","year":"2023","unstructured":"Davis AG, Wasserman S, Stek C, et al. A phase\u00a02A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial. Clin Infect Dis. 2023;76(8):1412\u201322.","journal-title":"Clin Infect Dis"},{"key":"1256_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1224179","volume":"10","author":"Z Xu","year":"2023","unstructured":"Xu Z, Zhang J, Guan T, et al. Case report: successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid. Front Med. 2023;10:1224179.","journal-title":"Front Med"},{"issue":"2","key":"1256_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106875","volume":"62","author":"W Guo","year":"2023","unstructured":"Guo W, Hu M, Xu N, et al. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: a case report. Int J Antimicrob Agents. 2023;62(2):106875.","journal-title":"Int J Antimicrob Agents"},{"key":"1256_CR56","volume":"2025","author":"Q Fan","year":"2025","unstructured":"Fan Q, Sun H, Liu S. Treatment of tuberculous meningitis with contezolid in a patient with complex comorbidities: a case report and literature review. Case Rep Infect Dis. 2025;2025:8814569.","journal-title":"Case Rep Infect Dis"},{"issue":"15","key":"1256_CR57","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.2147\/IDR.S373082","volume":"12","author":"Y Kang","year":"2022","unstructured":"Kang Y, Ge C, Zhang H, Liu S, Guo H, Cui J. Compassionate use of contezolid for the treatment of tuberculous pleurisy in a patient with a leadless pacemaker. Infect Drug Resist. 2022;12(15):4467\u201370.","journal-title":"Infect Drug Resist"},{"key":"1256_CR58","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2147\/IDR.S465350","volume":"17","author":"W Liu","year":"2024","unstructured":"Liu W, Yang L, Qin H, Zhang P. Successful treatment of intractable tuberculous peritonitis in a woman with chronic kidney allograft dysfunction using contezolid containing regimen. Infect Drug Resist. 2024;17:2713\u20138.","journal-title":"Infect Drug Resist"},{"key":"1256_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05128-2","author":"W Ding","year":"2025","unstructured":"Ding W, Shen L, Li R, Yang X, Wang Y, Luo Y. Treatment of pre-extensively drug-resistant tuberculosis in a 4-month-old infant using a regimen of bedaquiline, delamanid, and contezolid. Eur J Clin Microbiol Infect Dis. 2025. https:\/\/doi.org\/10.1007\/s10096-025-05128-2.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"1256_CR60","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/INF.0000000000004369","volume":"43","author":"S Shi","year":"2024","unstructured":"Shi S, Feng B, Li D, Sun M, Gai Q, Lin M. Treatment of tuberculous pleurisy with contezolid in a child with glucose-6-phosphate dehydrogenase deficiency: the first case report. Pediatr Infect Dis J. 2024;43(9):869\u201371.","journal-title":"Pediatr Infect Dis J"},{"key":"1256_CR61","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.2147\/IDR.S468543","volume":"17","author":"X Ma","year":"2024","unstructured":"Ma X, Zhang R, Cai X, Lang Y, Wang H, Li J. Plasma concentrations of contezolid and its efficacy and safety in elderly patients with multidrug-resistant tuberculosis and renal insufficiency. Infect Drug Resist. 2024;17:3047\u201356.","journal-title":"Infect Drug Resist"},{"issue":"02","key":"1256_CR62","first-page":"123","volume":"47","author":"W Nie","year":"2025","unstructured":"Nie W, Chu N. Expert consensus on the treatment of tuberculosis with contezolid. Chin J Antituberculosis 2025;47(02):123\u2013129.","journal-title":"Chin J Antituberculosis"},{"issue":"07","key":"1256_CR63","first-page":"830","volume":"47","author":"N Chu","year":"2025","unstructured":"Chu N, Nie W. Expert consensus on all-oral short-course therapy for drug-resistant tuberculosis. Chin J Antituberculosis 2025:47(07):830\u2013839.","journal-title":"Chin J Antituberculosis"},{"key":"1256_CR64","unstructured":"Zhang P, Tao C, Senlin Z, et al. Early bactericidal activity of contezolid in patients with drug-resistant tuberculosis. In ESCMID Global; 2025:P0589."},{"issue":"1","key":"1256_CR65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jiph.2023.11.012","volume":"17","author":"S Ramesh Kumar","year":"2024","unstructured":"Ramesh Kumar S, Narendran G, Padmapriyadarsini C. Role for linezolid in drug sensitive tuberculosis. J Infect Public Health. 2024;17(1):172\u20134.","journal-title":"J Infect Public Health"},{"issue":"10","key":"1256_CR66","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa2212537","volume":"388","author":"NI Paton","year":"2023","unstructured":"Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. New Engl J Med. 2023;388(10):873\u201387.","journal-title":"New Engl J Med"},{"issue":"4","key":"1256_CR67","doi-asserted-by":"publisher","first-page":"e02012","DOI":"10.1128\/AAC.02012-19","volume":"64","author":"AH Diacon","year":"2020","unstructured":"Diacon AH, De Jager VR, Dawson R, et al. Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis. Antimicrob Agents Chemother. 2020;64(4):e02012-e2019.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1256_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214037","volume":"14","author":"F Okazaki","year":"2019","unstructured":"Okazaki F, Tsuji Y, Seto Y, Ogami C, Yamamoto Y, To H. Effects of a rifampicin pre-treatment on linezolid pharmacokinetics. PLoS ONE. 2019;14(9):e0214037.","journal-title":"PLoS ONE"},{"issue":"12","key":"1256_CR69","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/jac\/dkad316","volume":"78","author":"M Bock","year":"2023","unstructured":"Bock M, Van Hasselt JGC, Schwartz F, et al. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis. J Antimicrob Chemother. 2023;78(12):2840\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1256_CR70","doi-asserted-by":"publisher","first-page":"1260535","DOI":"10.3389\/fphar.2023.1260535","volume":"14","author":"P Yan","year":"2023","unstructured":"Yan P, Shi QZ, Hu YX, Zeng Y, Lu H. Evaluation of the impact of rifampicin on the plasma concentration of linezolid in tuberculosis co-infected patients. Front Pharmacol. 2023;14:1260535.","journal-title":"Front Pharmacol"},{"key":"1256_CR71","unstructured":"Youxitai (Contezolid Tablets) [package insert]. Shanghai Micurx Pharmaceutical Co., Ltd.; 2023."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01256-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:02:37Z","timestamp":1767873757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01256-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Weili Li, Tao Chen, and Fangxue Shen are employed by Shanghai MicuRx Pharmaceutical Co., Ltd. Wenjuan Nie and Fan Wu have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}